[CAS NO. 1461640-62-9] Isatuximab

Name: Isatuximab
Brand: Arctom Scientific
SKU: HY-P9976

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1461640-62-9]

Distributor

Catalog

HY-P9976

Brand

MCE

CAS

1461640-62-9

DESCRIPTION [1461640-62-9]

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Isatuximab]

For research use only. We do not sell to patients.

Summary

Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38 , a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions ^[1] ^[2] .

In Vitro

An in-vitro study shows that the combination of Isatuximab with Pomalidomide (an immunomodulatory drug) results in greater direct toxicity and lysis of CD38 multiple myeloma cells by effector cells compared with Isatuximab alone ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04763616	Won Seog Kim\|Sanofi\|Samsung Medical Center	Natural Killer+T-cell Lymphoma\|Relapsed Natural Killer+T-cell Lymphoma\|Refractory Natural Killer+T-cell Lymphoma	June 25, 2021	Phase 2
NCT04883242	University of Washington\|Genzyme, a Sanofi Company	Recurrent Plasma Cell Myeloma\|Refractory Plasma Cell Myeloma	July 29, 2021	Phase 2
NCT05145400	UNC Lineberger Comprehensive Cancer Center\|Genzyme, a Sanofi Company	Multiple Myeloma\|Cancer	February 18, 2022	Phase 2
NCT04643002	Sanofi	Plasma Cell Myeloma Refractory	January 25, 2021	Phase 1\|Phase 2
NCT02999633	Sanofi	T-cell Type Acute Leukemia-Precursor\|T-lymphoblastic Lymphoma+Leukaemia	March 8, 2017	Phase 2
NCT05405166	Sanofi	Plasma Cell Myeloma Recurrent	June 23, 2022	Phase 3
NCT01749969	Sanofi	Plasma Cell Myeloma	February 6, 2013	Phase 1
NCT04786028	Canadian Myeloma Research Group	Multiple Myeloma	December 8, 2021	Phase 2
NCT04754945	Emory University\|Sanofi\|National Cancer Institute (NCI)	AL Amyloidosis	April 28, 2021	Phase 1
NCT03637764	Sanofi	Neoplasm	August 6, 2018	Phase 1\|Phase 2
NCT03989414	Celgene	Multiple Myeloma	September 30, 2019	Phase 1\|Phase 2
NCT04558931	Karolinska Institutet\|Sanofi	Multiple Myeloma	June 2, 2021	Phase 2
NCT02514668	Sanofi	Plasma Cell Myeloma	September 1, 2015	Phase 1
NCT03530683	Pfizer	Lymphoma\|Multiple Myeloma\|Acute Myeloid Leukemia\|Diffuse Large B-Cell Lymphoma	June 7, 2018	Phase 1
NCT05066607	Intergroupe Francophone du Myelome\|Sanofi\|Bristol-Myers Squibb	AL Amyloidosis	February 11, 2022	Phase 2
NCT04287855	Poitiers University Hospital\|Sanofi\|Celgene\|Amgen\|Intergroupe Francophone du Myelome	Multiple Myeloma in Relapse\|Multiple Myeloma, Refractory	August 28, 2020	Phase 2
NCT05346809	Divaya Bhutani\|Genzyme, a Sanofi Company\|Columbia University	Lymphoma\|Multiple Myeloma\|Non-Hodgkin Lymphoma\|Relapsed Hodgkin´s Disease, Adult	February 9, 2022	Phase 2
NCT03104842	Universitätsklinikum Hamburg-Eppendorf	Multiple Myeloma	August 15, 2017	Phase 2
NCT03617731	University of Heidelberg Medical Center	Multiple Myeloma	October 18, 2018	Phase 3
NCT03275285	Sanofi	Plasma Cell Myeloma	October 25, 2017	Phase 3
NCT03319667	Sanofi	Plasma Cell Myeloma	December 7, 2017	Phase 3
NCT03367819	Sanofi	Prostate Cancer\|Non-small Cell Lung Cancer	January 4, 2018	Phase 1\|Phase 2
NCT04045795	Sanofi	Multiple Myeloma	August 6, 2019	Phase 1
NCT03769181	Sanofi	Lymphoma	December 11, 2018	Phase 1\|Phase 2
NCT05298683	Hellenic Society of Hematology\|Sanofi	Multiple Myeloma\|Renal Impairment\|Neoplasms, Plasma Cell\|Neoplasms by Histologic Type\|Neoplasms\|Paraproteinemias\|Blood Protein Disorders\|Hematologic Diseases	May 2022	Phase 2
NCT03733717	Sanofi	Multiple Myeloma	October 22, 2018	Phase 1
NCT04943302	Tufts Medical Center\|Sanofi	Amyloidosis\|Light Chain (AL) Amyloidosis	September 2022	Phase 2
NCT04850599	OHSU Knight Cancer Institute\|Oregon Health and Science University\|Sanofi	Recurrent Plasma Cell Myeloma\|Refractory Plasma Cell Myeloma	June 14, 2022	Phase 2
NCT02283775	Sanofi	Plasma Cell Myeloma	May 15, 2015	Phase 1
NCT02990338	Sanofi	Plasma Cell Myeloma	December 22, 2016	Phase 3
NCT02960555	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Smoldering Plasma Cell Myeloma	February 8, 2017	Phase 2
NCT05344833	University of Illinois at Chicago	Multiple Myeloma	December 2022	Phase 2
NCT04835129	Medical College of Wisconsin	Multiple Myeloma	January 10, 2022	Phase 2
NCT04912427	Washington University School of Medicine\|Sanofi	Multiple Myeloma	April 1, 2022	Phase 1
NCT04614558	Columbia University\|Genzyme, a Sanofi Company	Monoclonal Gammopathy	June 8, 2021	Phase 2
NCT05558319	PETHEMA Foundation\|Bristol-Myers Squibb\|Sanofi\|Adknoma\|Start from scratch	Newly Diagnosed Multiple Myeloma	October 2022	Phase 3
NCT04294459	Sanofi	Immune System Disorder	June 18, 2020	Phase 1\|Phase 2
NCT02513186	Sanofi	Plasma Cell Myeloma	September 30, 2015	Phase 1
NCT04483739	European Myeloma Network\|EMN Research Italy\|Sanofi\|Amgen	Multiple Myeloma	September 25, 2020	Phase 3
NCT04934475	Intergroupe Francophone du Myelome\|Amgen\|Sanofi\|Bristol-Myers Squibb	Multiple Myeloma	December 8, 2021	Phase 3
NCT04240054	Medical College of Wisconsin	Multiple Myeloma	November 2, 2021	Phase 2
NCT05559827	Assistance Publique - Hôpitaux de Paris	Immunological Pure Red Cell Aplasia	September 2022	Phase 2
NCT02812706	Sanofi	Multiple Myeloma	September 5, 2016	Phase 1\|Phase 2
NCT04083898	Washington University School of Medicine\|Sanofi	Multiple Myeloma	April 3, 2020	Phase 1\|Phase 2
NCT04661033	Sanofi	Warm Autoimmune Hemolytic Anemia (wAIHA)	September 9, 2021	Phase 1\|Phase 2
NCT02332850	Thomas Martin, MD\|Amgen\|Sanofi\|University of California, San Francisco	Multiple Myeloma	January 21, 2015	Phase 1
NCT03194867	Sanofi	Plasma Cell Myeloma	January 25, 2018	Phase 1\|Phase 2
NCT04653246	Jacob Laubach\|Sanofi\|Dana-Farber Cancer Institute	Multiple Myeloma\|Newly Diagnosed Multiple Myeloma (NDMM)\|Autologous Stem Cell Transplant	July 13, 2021	Phase 2
NCT03499808	Southwest Oncology Group\|National Cancer Institute (NCI)	Amorphous, Eosinophilic, and Acellular Deposit\|Constipation\|Diarrhea\|Early Satiety\|Gastrointestinal Hemorrhage\|Hepatomegaly\|Lymphadenopathy\|Macroglossia\|Nausea\|Primary Systemic Amyloidosis\|Purpura\|Recurrent Primary Amyloidosis\|Refractory Primary Amyloidosis	March 8, 2018	Phase 2
NCT03860844	Sanofi	Acute Lymphoblastic Leukemia\|Acute Myeloid Leukemia	August 6, 2019	Phase 2
NCT04458831	Sanofi	Plasma Cell Myeloma	August 13, 2020
NCT04126200	GlaxoSmithKline	Multiple Myeloma	October 7, 2019	Phase 1\|Phase 2
NCT04270409	Sanofi	Plasma Cell Myeloma	June 16, 2020	Phase 3
NCT05284032	Firas El Chaer, MD\|University of Virginia	Platelet Refractoriness\|Hematologic Malignancy	November 4, 2022	Early Phase 1
NCT05114109	Assistance Publique - Hôpitaux de Paris	Multiple Myeloma\|Monoclonal Gammopathy of Undetermined Significance\|Cryoglobulinemic Vasculitis	November 1, 2021	Phase 2
NCT04751877	Poitiers University Hospital\|Intergroupe Francophone du Myelome\|Sanofi	Multiple Myeloma\|Myeloma	July 17, 2021	Phase 3
NCT05147493	Hellenic Society of Hematology\|Sanofi	Multiple Myeloma\|Renal Impairment\|Neoplasms, Plasma Cell\|Neoplasms by Histologic Type\|Neoplasms\|Paraproteinemias\|Blood Protein Disorders\|Hematologic Diseases	April 2022	Phase 2
NCT03555149	Hoffmann-La Roche	Colorectal Cancer	September 27, 2018	Phase 1\|Phase 2
NCT01084252	Sanofi	Hematological Malignancy	June 10, 2010	Phase 1\|Phase 2
NCT04430894	Massachusetts General Hospital\|Amgen\|Sanofi	Multiple Myeloma	July 10, 2020	Phase 2
NCT04802031	Thomas Martin, MD\|University of California, San Francisco	Relapsed Multiple Myeloma\|Refractory Multiple Myeloma	May 28, 2021	Phase 2
NCT05123131	Cancer Trials Ireland\|Sanofi\|Dana-Farber Cancer Institute	Multiple Myeloma	April 1, 2022	Phase 2

Appearance

Liquid

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.